The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells.


Previous studies demonstrated that imatinib mesylate (IM) induces autophagy in chronic myeloid leukemia (CML) and that this process is critical to cell survival upon therapy. However, it is not known if the autophagic process differs at basal levels between CML patients and healthy individuals and if pretreatment CML cells harbor unique autophagy… (More)
DOI: 10.1182/blood-2013-07-516807


8 Figures and Tables